These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 19764574)

  • 1. [Clinical pharmacokinetics/pharmacodynamics study on pazufloxacin methanesulphonate injection].
    Wang XG; Miao J; Liang DR; Yu Q; Liang MZ; Zhang SH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):689-93. PubMed ID: 19764574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.
    Nakamura K; Ikawa K; Nishikawa G; Kobayashi I; Narushima M; Muramatsu H; Morinaga S; Kajikawa K; Kato Y; Watanabe M; Zennami K; Kanao K; Morikawa N; Sumitomo M
    J Infect Chemother; 2017 Dec; 23(12):809-813. PubMed ID: 28923301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
    Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
    J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the resistance of methicillin-resistant staphylococcus aureus to iodophor and chlorhexidine].
    Zhang YH; Liu XY; Zhu LL; Yu YZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Mar; 25(3):248-50. PubMed ID: 15200941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of target attainment rate of pazufloxacin mesilate using Monte Carlo simulation method].
    Abe N; Fukuda S; Nakamura A; Taguchi Y; Matsuo S
    Jpn J Antibiot; 2010 Aug; 63(4):319-25. PubMed ID: 21298865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits.
    Fernández-Varón E; Marin P; Escudero E; Vancraeynest D; Cárceles CM
    J Vet Pharmacol Ther; 2007 Feb; 30(1):18-24. PubMed ID: 17217396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species.
    Higa F; Akamine M; Haranaga S; Tohyama M; Shinzato T; Tateyama M; Koide M; Saito A; Fujita J
    J Antimicrob Chemother; 2005 Dec; 56(6):1053-7. PubMed ID: 16260445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
    Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
    J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus].
    Maekawa M; Takahashi K; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects in vitro of tea tree oil and plaunotol on methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus.
    Hada T; Furuse S; Matsumoto Y; Hamashima H; Masuda K; Shiojima K; Arai T; Sasatsu M
    Microbios; 2001; 106 Suppl 2():133-41. PubMed ID: 11548201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of 2-arylbenzofurans from Morus species against methicillin-resistant Staphylococcus aureus.
    Fukai T; Kaitou K; Terada S
    Fitoterapia; 2005 Dec; 76(7-8):708-11. PubMed ID: 16236463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
    Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
    Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacin in the bile of patients undergoing biliary pancreatic surgery.
    Uegami S; Ikawa K; Ohge H; Nakashima A; Shigemoto N; Morikawa N; Murakami Y; Sueda T
    J Chemother; 2014 Oct; 26(5):287-92. PubMed ID: 24552254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
    Cetinkaya E; Coban AY; Durupinar B
    Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Activity of vancomycin and teicoplanin against clinical isolates of Staphylococcus aureus in the period 1994-1999].
    Nashev D; Toshkova K; Gavrilova V
    Vutr Boles; 2000; 32(2):35-40. PubMed ID: 11227664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.